Mutational Landscape of MPN; Emerging JAK Inhibitors; Ruxolitinib Combination Trials; Anti-Fibrotic Agents

Angela Fleischman, MD, PhD of University of California, Irvine discusses Mutational Landscape of MPN; Emerging JAK Inhibitors; Ruxolitinib Combination Trials; Anti-Fibrotic Agents at Spotlight on ASH Thursday, January 28, 2016 Fairmont Newport Beach